Edition:
United States

Innate Pharma SA (IPH.PA)

IPH.PA on Paris Stock Exchange

7.74EUR
14 Dec 2018
Change (% chg)

€-0.19 (-2.40%)
Prev Close
€7.93
Open
€7.81
Day's High
€7.95
Day's Low
€7.66
Volume
366,257
Avg. Vol
344,591
52-wk High
€9.44
52-wk Low
€4.41

Select another date:

Tue, Dec 4 2018

BRIEF-Innate Pharma Announces Updated Results On IPH4102

* ANNOUNCED ON MONDAY UPDATED RESULTS THAT SUPPORT ADVANCEMENT OF IPH4102 IN REFRACTORY SÉZARY SYNDROME

AstraZeneca digs deeper into cancer with Innate stake

LONDON/PARIS AstraZeneca is plowing deeper into cancer immunotherapy through a wide-ranging deal with Innate Pharma, which includes the British group buying a 9.8 percent stake in the French biotech company.

UPDATE 2-AstraZeneca digs deeper into cancer with Innate stake

* Innate shares jump 29 percent (Updates with executive interviews, latest shares)

AstraZeneca to buy 9.8 pct stake in France's Innate Pharma

PARIS, Oct 23 British drugmaker AstraZeneca will buy a newly-issued equity stake of 9.8 percent in smaller French peer Innate Pharma, strengthening its presence in the field of immuno-oncology.

BRIEF-Innate Pharma: Phase II Results From Monalizumab/Cetuximab In Head And Neck Cancer

* INNATE PHARMA ANNOUNCED ON SATURDAY PHASE II RESULTS FROM MONALIZUMAB/CETUXIMAB IN HEAD AND NECK CANCER

BRIEF-Innate Pharma Publishes Phase 1 IPH4102 Results

* REPORTED ON SATURDAY IPH4102 PHASE 1 RESULTS IN ADVANCED CUTEANOUS T CELL LYMPHOMA

Select another date: